Lundbeck's antidepressant Lexapro storms ahead in US  

Danish pharmaceutical company Lundbeck has posted Q2 results showing a 47% increase in earnings for Lexapro on the US market
Danish pharmaceutical company Lundbeck has posted second quarter results showing a strong advance of its antidepressant drug Lexapro (escitalopram) on the US market. Q2 earnings were up no less than 47% on the same quarter last year, up DKK 206 m (USD 37.4 m) to DKK 641 m (USD 116.2 m).
The rapid rise was brought about partly because US collaboration partner Forest Laboratories had run down stock levels during 2006, but also because Lexapro had gained market share significantly. Lexapro's current share of the total antidepressant market in the US is 22.1%, compared with 17.1% during the same period last year.
In Europe, where the drug is marketed under the name Cipralex, progress was somewhat more modest. At the end of May, Cipralex had a 14.4% share of the total antidepressant market compared with 13.5% in February. The news was reported by financial daily newspaper Børsen.
Lundbeck is an international pharmaceutical company engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company generated revenues of DKK 9.2 billion (USD 1.67 bn). Lundbeck is headquartered in Copenhagen and employs approx 5,300 people globally.
Link > Lundbeck   

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×